anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides an injection-use ciprofloxacin composition lyophilized powder injection, and relates to the technical field of medicine and medicine preparation. The injection comprises the raw material components of, by weight: 2-7 parts of ciprofloxacin hydrochloride (calculated according to ciprofloxacin), 1.5-3.5 parts of chitosan nano-particles, and 89.5-95.5 parts of injection water. The injection has the advantages that: the composition is a mixture of ciprofloxacin and chitosan nano-particles with an appropriate ratio. The two components have synergetic effect. The composition is prepared into injection-use lyophilized powder injection which is clinically applied as a novel antibacterial medicine. The injection has the advantages that: (1) the injection is a clinically developed novel medicine preparation; (2) the formula is reasonable, and medicine dissolubility is increased; (3) production process is advanced, preparation is stable, and storage life is long; (4) the effect is fast; antibacterial activity is enhanced with the synergetic effect; and bioavailability is high; (5) active effect of mannitol to human body is eliminated; medicine potential adverse reaction is reduced; application is safe; treatment effect is clear; and quality is controllable; and (6) dose is accurate, and application is convenient.
Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ESKETINTRD3004 (NCT02497287), or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
Clinical Information Systems (CIS) may combine evidence-based and best-practice diagnosis and treatment of care delivery into an electronic workflow with clinical decision support (CDS) tools (e.g. order sets, structure documentation, rule-based alerts, compliance and performance reports) to improve care delivery. Configurating CIS's has required manually intensive processes and clinical experts to determine mapping of clinical concepts in the CDS to the CIS. Changes in medicine change configuration requirements causing changes to data structure, semantics, and even historical information. Traditional mapping is non-explicit and hard coded with a high effort cost for reconfiguration, interoperability, and quality assessment. Using Semantic Context Maps, simultaneously mapping naturally stated, native encoding, and semantic encoding in a clinical context, provides simplification of configuration of CDS and increases value of clinical information as medicine evolves. The invention constructs semantically encoded clinical data using semantic context mapping to enable analytics using semantic processing instead of traditional query analytics.
AZSTARYS has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction [see Warnings and Precautions (5.1)]. AZSTARYS can be diverted for non-medical use into illicit channels or distribution.

Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of the combination of dexmethylphenidate and serdexmethylphenidate may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including AZSTARYS, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Cases of life-threatening hepatic failure have been reported in patients treated with zafirlukast. Cases of liver injury without other attributable cause have been reported from post-marketing adverse event surveillance of patients who have received the recommended dose of zafirlukast (40 mg/day). In most, but not all post-marketing reports, the patient’s symptoms abated and the liver enzymes returned to normal or near normal after stopping zafirlukast. In rare cases, patients have either presented with fulminant hepatitis or progressed to hepatic failure, liver transplantation and death. In extremely rare post-marketing cases, no clinical symptoms or signs suggestive of liver dysfunction were reported to precede the latter observations.

Physicians may consider the value of liver function testing. Periodic serum transaminase testing has not proven to prevent serious injury but it is generally believed that early detection of drug-induced hepatic injury along with immediate withdrawal of the suspect drug enhances the likelihood for recovery.

Patients should be advised to be alert for signs and symptoms of liver dysfunction (eg, right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, and anorexia) and to contact their physician immediately if they occur. Ongoing clinical assessment of patients should govern physician interventions, including diagnostic evaluations and treatment.

If liver dysfunction is suspected based upon clinical signs or symptoms (eg, right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, anorexia, and enlarged liver), zafirlukast should be discontinued. Liver function tests, in particular serum ALT, should be measured immediately and the patient managed accordingly. If liver function tests are consistent with hepatic dysfunction, zafirlukast therapy should not be resumed. Patients in whom zafirlukast was withdrawn because of hepatic dysfunction where no other attributable cause is identified should not be re-exposed to zafirlukast (see PRECAUTIONS, Information for Patients and ADVERSE REACTIONS).
The invention relates to a medicine liquid used for treating dementia. The invention belongs to the technical field of Chinese and Western medicine combined preparation. The medicine liquid is mainly composed of 12 traditional Chinese medicines such as sharpleaf uncaria stem with hooks, thinleaf milkwort root, tatarinow sweetflag rhizome, golden thread, amur corktree bark, and suffrutescent flueggea herb; 3 Western medicines such as musk injection and aminobutyric acid injection; and an auxiliary material which is distillate spirit. The ratio of the traditional Chinese medicine to the Western medicine to the auxiliary material is 1.2-0.7:2. The medicine liquid is an external solution, and provides functions such as kidney nourishing, heart nourishing, blood circulation activating, stasis removing, refreshing, resuscitation, brain cell activating, brain cell protecting, and brain cell repairing. When the medicine liquid is used for treating dementia, purposes of clear treatment effect and no toxic or side effect are achieved.
PURPOSE:To obtain cosmetic and powder cosmetic having excellent transparency, stability and utility, having no influence on other components in cosmetic, showing stabilizing effects on the other components for a long period of time, containing an inclusion compound comprising slight water-soluble components included in a specific mixture. CONSTITUTION:A cosmetic or powder cosmetic containing an inclusion compound prepared by including Macadamia nut, vitamin E acetate, 2-hydroxy-4- methoxybenzophenone, etc., in a mixture of cyclodextrin polymer (CDP for short) and a hydroxyalkylated cyclodextrin (HACD for short). The blending ratio of CDP and HACD is (1:9)-(9:1), preferably (2:8)-(7:3) by weight. An ordinary blending is used as the blending method. The cosmetic is completely dissolved in a small amount of water to improve utility and stability. The cosmetic is useful for toilet lotion, lotion, solution for beauty culture, foundation, lipstick, eye liner, etc.
The utility model describes a process of producing anti-parasitic soap using 84 pcnt glycerine bar, 15 pcnt tubli vine extract (Derris elliptica Benth) and 1 pcnt virgin coconut oil. Preferable tubli vine extract is the roots of tubli vine. The said soap is effective in killing lice, ticks, mites and fleas in dogs and cats. The soap could also be applied to other animals. A process of producing soap for animals comprising the following steps: harvesting tubli vine (Derris e/liptica Benth). Grind the vine to make it fine. Extraction of vines with distilled water using blender. Stain the extract to eliminate the sap. Measure 84 pcnt by weight of glycerine Bar and melt glycerine bar in a medium heat pan. Add 15 pcnt by weight Tubli vine extract (Derris elliptica Benth) to the melted glycerine. Continuous stirring to attained homogenous mixture and add 1 pcnt by weight Virgin coconut oil. Dispense the mixture into moulder. Let the mixture to cool down for 48hours. Slice the soap into desited tut.
Reports of necrotizing fasciitis of the perineum (Fournier’s Gangrene), a rare but serious and life-threatening necrotizing infection requiring urgent surgical intervention, have been identified in postmarketing surveillance in patients with diabetes mellitus receiving SGLT2 inhibitors, including dapagliflozin. Cases have been reported in both females and males. Serious outcomes have included hospitalization, multiple surgeries, and death.

Patients treated with XIGDUO XR presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise, should be assessed for necrotizing fasciitis. If suspected, start treatment immediately with broad-spectrum antibiotics and, if necessary, surgical debridement. Discontinue XIGDUO XR, closely monitor blood glucose levels, and provide appropriate alternative therapy for glycemic control.
Transplantation of brown adipose tissue (BAT) is a promising approach for treating obesity and metabolic disorders. However, obtaining sufficient amounts of functional BAT or brown adipocytes for transplantation remains a major challenge. In this study, we developed a hydrogel that combining adipose acellular matrix (AAM) and GelMA and HAMA that can be adjusted for stiffness by modulating the duration of light-crosslinking. We used human white adipose tissue-derived microvascular fragments to create beige adipose organoids (BAO) that were encapsulated in either a soft or stiff AAM hydrogel. We found that BAOs cultivated in AAM hydrogels with high stiffness demonstrated increased metabolic activity and upregulation of thermogenesis-related genes. When transplanted into obese and type 2 diabetes mice, the HFD + BAO group showed sustained improvements in metabolic rate, resulting in significant weight loss and decreased blood glucose levels. Furthermore, the mice showed a marked reduction in nonalcoholic liver steatosis, indicating improved liver function. In contrast, transplantation of 2D-cultured beige adipocytes failed to produce these beneficial effects. Our findings demonstrate the feasibility of fabricating beige adipose organoids in vitro and administering them by injection, which may represent a promising therapeutic approach for obesity and diabetes.
Tendon pain is a common complaint in older adults. The mechanisms contributing to the large number of tendon problems in older adults are not known. It has been shown that tendon cross-sectional area (CSA) is reduced with aging concurrent with a significant loss of tendon collagen. Exercise is used to reverse the loss of muscle mass with aging but surprisingly exercise interventions designed to reduce tendon problems in older people are relatively unexplored. In young adults, exercise stimulates tendon collagen synthesis and enhances the production of growth factors, which stimulate tendon collagen production. It is presumed that exercise-induced increase in collagen synthesis contributes to the increase in tendon stiffness and CSA noted in young adults after chronic resistance exercise (RE). In contrast, our preliminary work indicates that RE is not effective at reducing the effects of aging on tendon. The investigators have demonstrated that 12-weeks of RE does not lead to increases in tendon CSA or stiffness, even when skeletal muscle mass and strength are greatly enhanced. To prevent tendon injury, greater tendon CSA and stiffness aid in withstanding the force generated by trained skeletal muscle. Greater CSA and stiffness also optimize force transfer through tendon to maximize musculoskeletal function. Our findings indicate that RE is not an optimal intervention for reversing age-related changes in tendon properties. Novel interventions are clearly needed that will enhance collagen synthesis leading to an increase in tendon stiffness and CSA while also improving skeletal muscle mass and strength in older individuals. This study will evaluate the effectiveness of various methods for stimulating tendon collagen synthesis during a bout of acute exercise. Specifically, the investigators propose two approaches to this problem.

1. An acute bout of cycling exercise will enhance the release of growth factors leading to a larger increase in tendon collagen synthesis.
2. A bolus of amino acids given orally will increase the release of key stimulators of tendon collagen synthesis leading to enhanced collagen synthesis after acute exercise.
Minding the Baby is an intensive and preventive home-visiting programme that helps vulnerable or high risk mothers. The focus of the intervention is to reduce negative infant and maternal outcomes and strengthen the attachment relationship. MTB is delivered by an interdisciplinary team of highly skilled practitioners, who have health and social work experience, integrating advanced practice nursing and mental health care for mothers and infants. In the proposed Randomised Control Trial (RCT) the investigators will study the efficacy of this innovative intervention across ten Danish sites. Site staff will be trained at two sessions one year apart. Sites are randomized to training at time 1 or 2. All sites will recruit treatment as usual control families before they receive the training and start offering the intervention to all families. Potential participants will be approached by a local front staff member (e.g. midwife, helath visitor or social worker) who will inform mothers of the project in the early pregnancy. Consenting eligible participants will be assessed before they give birth and when their child is three months, one and two years old.

The effectiveness of the MTB programme will be evaluated by assessing a range of maternal and infant outcomes, including maternal sensitivity, parent mental Health, child development, and register data on e.g. infant maltreatment and neglect, hospitalization, income, immunization. By combining parent report, observational and register data researchers will get a unique opportunity to advance knowledge regarding effective ways to support some of the youngest and most vulnerable children in Denmark.
Risk Summary

Based on its mechanism of action and findings from animal studies [see Clinical Pharmacology (12.1), Nonclinical Toxicology (13.1)], MYLOTARG can cause embryo-fetal harm when administered to a pregnant woman. There are no available data on MYLOTARG use in pregnant women to evaluate for a drug-associated risk. In animal reproduction studies, gemtuzumab ozogamicin caused embryo-fetal toxicity, including structural abnormalities and alterations to growth, at maternal systemic exposures that were greater than or equal to 0.4 times the exposure in patients at the maximum recommended dose based on AUC (see Data). Advise pregnant women of the potential risk to a fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.

Data

Animal Data

In an embryo-fetal development study in rats, pregnant animals received daily intravenous doses up to 1.2 mg/m2/day gemtuzumab ozogamicin during the period of organogenesis. Embryo-fetal toxicities including fetal growth retardation as evidenced by decreased live fetal weights, incidence of fetal wavy ribs and delayed skeletal ossification were observed at greater than or equal to 0.15 mg/m2/day. Increased embryo-fetal lethality and fetal morphological anomalies (digital malformations, absence of the aortic arch, anomalies in the long bones in the forelimbs, misshapen scapula, absence of a vertebral centrum, and fused sternebrae) were observed at greater than or equal to 0.36 mg/m2/day. All doses with embryo-fetal effects were observed in the presence of maternal toxicity that included decreases in gestational body weight gain, food consumption, and gravid uterine weight. The lowest dose at which embryo-fetal effects were observed in rats (0.15 mg/m2/day) was 0.4 times the exposure in patients at the maximum recommended human dose, based on AUC.
Risk Summary

Warfarin sodium tablets, USP are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism, and for whom the benefits of warfarin sodium may outweigh the risks [see Warnings and Precautions (5.7)]. Warfarin sodium can cause fetal harm. Exposure to warfarin during the first trimester of pregnancy caused a pattern of congenital malformations in about 5% of exposed offspring. Because these data were not collected in adequate and well-controlled studies, this incidence of major birth defects is not an adequate basis for comparison to the estimated incidences in the control group or the U.S. general population and may not reflect the incidences observed in practice. Consider the benefits and risks of warfarin sodium and possible risks to the fetus when prescribing warfarin sodium to a pregnant woman.

Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

In humans, warfarin crosses the placenta, and concentrations in fetal plasma approach the maternal values. Exposure to warfarin during the first trimester of pregnancy caused a pattern of congenital malformations in about 5% of exposed offspring. Warfarin embryopathy is characterized by nasal hypoplasia with or without stippled epiphyses (chondrodysplasia punctata) and growth retardation (including low birth weight). Central nervous system and eye abnormalities have also been reported, including dorsal midline dysplasia characterized by agenesis of the corpus callosum, Dandy-Walker malformation, midline cerebellar atrophy, and ventral midline dysplasia characterized by optic atrophy. Mental retardation, blindness, schizencephaly, microcephaly, hydrocephalus, and other adverse pregnancy outcomes have been reported following warfarin exposure during the second and third trimesters of pregnancy [see Contraindications (4)].
Non-randomised control arm, where patients who are receiving a stem cell transplant, as described in the eligibility criteria, are asked for a blood sample. This is to establish a baseline versus the experimental arm. 20 participants will be approached for this arm.
Infusion Reactions

  * Serious and potentially life-threatening infusion reactions occurred in 26% of patients treated with Unituxin. Administer required prehydration and premedication including antihistamines prior to each Unituxin infusion. Monitor patients closely for signs and symptoms of an infusion reaction during and for at least four hours following completion of each Unituxin infusion. Immediately interrupt Unituxin for severe infusion reactions and permanently discontinue Unituxin for anaphylaxis (2.2, 2.3, 5.1).



Neurotoxicity

  * Unituxin causes serious neurologic adverse reactions including severe neuropathic pain and peripheral neuropathy.

Severe neuropathic pain occurs in the majority of patients. Administer intravenous opioid prior to, during, and for 2 hours following completion of the Unituxin infusion. 

In clinical studies of patients with high-risk neuroblastoma, Grade 3 peripheral sensory neuropathy occurred in 2% to 9% of patients. In clinical studies of Unituxin and related GD2-binding antibodies, severe motor neuropathy has occurred. Resolution of motor neuropathy did not occur in all cases. Discontinue Unituxin for severe unresponsive pain, severe sensory neuropathy, and moderate to severe peripheral motor neuropathy (2.2, 2.3, 5.2).
Remote ischemic conditioning paired with endovascular treatment. RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times. Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association. It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
Food agencies will see the behavioral economics (BE)-enhanced interface by default; food items will be sorted with green-labeled items listed first, followed by yellow, then red. If users search for a specific item type (e.g., chicken) the results returned for that item type will also be sorted so that green-labeled items are listed first. At any time during the ordering episode, users will have the option to switch from the BE-enhanced default to an alternate sorting or filtering choice, such as alphabetical or cost. Users will be shown the percent of items (by weight) that are labeled green in a prominent location on the ordering screen. The percent green-labeled items in the order will appear alongside messaging reporting the average percent green-labeled items ordered by GBFB pantries that rank in the top 10% based on this metric.